denkapparat Operations GmbH Purchases New Holdings in DexCom, Inc. $DXCM

denkapparat Operations GmbH acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,070 shares of the medical device company’s stock, valued at approximately $476,000.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC grew its position in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the last quarter. Empowered Funds LLC increased its stake in DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth increased its stake in DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares during the period. Finally, NewEdge Advisors LLC raised its position in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after buying an additional 258 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DXCM opened at $87.90 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The stock has a market cap of $33.17 billion, a P/E ratio of 34.74, a P/E/G ratio of 1.50 and a beta of 1.42. The stock’s 50 day simple moving average is $81.24 and its 200 day simple moving average is $72.35. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue was up 13.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 earnings per share. As a group, equities analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. Truist Financial set a $93.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Barclays reiterated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $94.00 target price on shares of DexCom in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $88.71.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 65,777 shares of company stock worth $4,950,714. Corporate insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.